Status:
COMPLETED
Efficacy and Safety of VA106483 in Elderly Males
Lead Sponsor:
Vantia Ltd
Collaborating Sponsors:
Veeda Clinical Research
Conditions:
Nocturia
Eligibility:
MALE
65+ years
Phase:
PHASE1
PHASE2
Brief Summary
A double blind, placebo-controlled, dose ranging study in males over the age of 65, who have a history of nocturia. The study will investigate pharmacodynamic outcomes (urine volumes and osmolality, c...
Detailed Description
VA106483 is a selective vasopressin V2 receptor agonist which is currently under development for the treatment of nocturia in males. This study examines the pharmacological action of VA106483 on marke...
Eligibility Criteria
Inclusion
- Males 65 years and above with history of nocturia
Exclusion
- Any clinically significant concomitant medical disease, condition or abnormal laboratory test result
- Participation in any other clinical study within 30 days
- Intake of non-prescription medication within 14 days
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00879138
Start Date
August 1 2008
End Date
March 1 2009
Last Update
October 31 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Veeda Clinical Research
Plymouth, United Kingdom